•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Zymeworks Announces $200 Million Share Repurchase Authorization
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Comparing Vericel (NASDAQ:VCEL) and Zymeworks (NASDAQ:ZYME)
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME
Zymeworks Completes Acquisition of Theravance Biopharma
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Jupiter Topco LLC Buys New Position in Zymeworks Inc. $ZYME
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval